CuraSen is expanding its pipeline with the launch of CuraAX in a Phase 1 clinical trial targeting neurogenic orthostatic hypotension (nOH), a sudden and dangerous drop in blood pressure upon standing that can cause debilitating dizziness, weakness, dangerous falls and cognitive decline. nOH often occurs in patients with Parkinson’s, Alzheimer's and other neurological diseases. CuraAX, also known as CST-3056, is a novel, alpha1A adrenergic agonist designed to improve cerebral blood flow, symptoms and cognition in nOH patients, with an enhanced safety profile. CuraAX is being developed with funding from the Alzheimer’s Drug Discovery Foundation (ADDF). https://lnkd.in/gprgAQpY #nOH#neurogenicorthostatichypotension#ADDF#alpha1aadrenergicagonism
CuraSen Therapeutics, Inc.
生物技术研究
San Carlos，California 958 位关注者
Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN
关于我们
It’s time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN. CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. At CuraSen, we are rethinking the therapeutic approach to treatment of neurodegenerative diseases—and advancing a concept based on restoring a key functionality to a pathway lost early in the degenerating brain. This pathway emanates from the locus coeruleus (LC), site of the earliest pathology seen in these diseases – perhaps the ‘hypocenter’ of neurodegeneration. We began clinical testing of our hypothesis in 2019 using established drugs from other therapeutic areas, which has informed our development program and helped advance our first new chemical entity, CST-2032, to the clinic in September 2020. CuraSen has assembled an impressive team, deeply experienced in the neuroscience, pharmacology and clinical development core to its approach, as well as top tier investor backing, including New Leaf Venture Partners, Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Pappas Capital.
- 网站
-
https://www.curasen.com
CuraSen Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Carlos，California
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Parkinson’s Disease, Alzheimer’s Disease、Locus Coeruleus、Neurodegeneration、Neuroinflammation、Neurometabolism和Cerebral Blood Flow
地点
-
主要
获取路线
930 Brittan Ave
#306
US，California，San Carlos，94070
CuraSen Therapeutics, Inc.员工
动态
-
We are pleased to announce the appointment of Kathleen Sereda Glaub, formerly executive chair, as chief executive officer. Dr. Anthony Ford will continue to lead CuraSen’s research and development as president and chief scientific officer. Patrick Enright, managing director of Longitude Capital, will become chair of the board. Along with these changes, we are expanding the indications addressed by our adrenergic activator drug candidates, including neurogenic orthostatic hypotension with Cura-AX (CST-3056), major depressive disorder in older adults with CuraCN, (formerly known as CST-103/CST-107) and Alzheimer’s disease with CuraXN (formerly known as CST-2032CST-107).https://lnkd.in/gfH4gHhE
-
-
CuraSen joins the international community in honoring the 10 million people living worldwide with Parkinson’s disease, a neurodegenerative disorder that affects predominately the dopamine-producing neurons in the brain. Parkinson’s causes both motor symptoms, such as tremor, muscle stiffness and impaired gait, and non-motor-symptoms, including declines in memory, attention, social cognition and executive functioning skills. Our Phase 2 compounds, CST-103 and CST-2032, have shown robust improvements in Parkinson’s and Alzheimer’s patients with mild cognitive impairment by restoring adrenergic function to the brain. We look forward to testing these compounds in longer, larger studies later this year. www.curasen.com/pipeline/. To learn more about Parkinson’s, please visit: https://lnkd.in/exBwUTwQ. #Parkinson's#Phase2clinicaltrials#mildcognitiveimpairment#MCI
-
-
?? New data from a phase 2a trial assessing CuraSen Therapeutics, Inc.'s combination adrenergic activator showed significant improvement with the treatment across several cognitive domains in patients with #MCI or mild dementia from either #AD or #PD. #ADPD2024 AD/PD - Advances in Science & Therapy https://lnkd.in/ejYwQD2g